Patrick Flume to Quality of Life
This is a "connection" page, showing publications Patrick Flume has written about Quality of Life.
Connection Strength
0.725
-
Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):737-742.
Score: 0.345
-
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016 07; 15(4):495-502.
Score: 0.071
-
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015 Jul; 14(4):507-14.
Score: 0.066
-
A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis. Chest. 2014 Aug; 146(2):437-448.
Score: 0.064
-
The clinical approach to lung disease in patients with cystic fibrosis. Semin Respir Crit Care Med. 2009 Oct; 30(5):505-13.
Score: 0.045
-
Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009 Apr; 54(4):522-37.
Score: 0.044
-
Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. Future Microbiol. 2021 09; 16:1087-1104.
Score: 0.026
-
The Impact of Respiratory Function on Voice in Patients with Presbyphonia. J Voice. 2022 Mar; 36(2):256-271.
Score: 0.024
-
Effect of pulmonary rehabilitation on quality of life in patients with COPD: the use of SF-36 summary scores as outcomes measures. J Cardiopulm Rehabil. 2000 Jul-Aug; 20(4):231-4.
Score: 0.024
-
Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014 Sep; 2(9):738-49.
Score: 0.016